VXA-G1.1-NN Oral Vaccine

Phase 1Completed

1 views this week 0 watching💤 Quiet

Interest: 19/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Norovirus Gastroenteritis

Conditions

Norovirus Gastroenteritis

Trial Timeline

Apr 7, 2017 → May 6, 2018

NCT ID

NCT03125473

About VXA-G1.1-NN Oral Vaccine

VXA-G1.1-NN Oral Vaccine is a phase 1 stage product being developed by Vaxart for Norovirus Gastroenteritis. The current trial status is completed. This product is registered under clinical trial identifier NCT03125473. Target conditions include Norovirus Gastroenteritis.

What happened to similar drugs?

0 of 1 similar drugs in Norovirus Gastroenteritis were approved

Approved (0) Terminated (0) Active (1)

🔄mRNA-1403ModernaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03125473	Phase 1	Completed	Apr 7, 2017	May 6, 2018	Norovirus Gastroenteritis

Competing Products

13 competing products in Norovirus Gastroenteritis

See all competitors

Product	Company	Stage	Hype Score
mRNA-1403	Moderna	Phase 2	0
mRNA-1403	Moderna	Phase 3	0
VXA-G1.1-NN + VXA-G2.4-NS + Placebo Tablets	Vaxart	Phase 1	19
VXA-G1.1-NN (high dose) Oral Vaccine Tablet + VXA-G1.1-NN (low dose) Oral Vaccine Tablet	Vaxart	Phase 1	19
VXA-G1.1-NN + VXA-G2.4-NS + VXA G1.1 NN-T + VXA G2.4 NS-T	Vaxart	Phase 1	23
VXA-G1.1-NN	Vaxart	Phase 1/2	22
VXA-G1.1-NN	Vaxart	Phase 1	19
Norwalk GI.1 Virus	Vaxart	Phase 1	19
VXA-G1.1-NN + Norovirus GI.1 Norwalk Virus Inoculum	Vaxart	Phase 1/2	22
Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose + Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose + Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose + Placebo	Vaxart	Phase 2	25
VXA-G1.1-NN + VXA-G2.4-NS + Placebo Tablets	Vaxart	Phase 1	19
VXA-GI.1.NN + Placebo Tablet	Vaxart	Phase 1	19
CDI-988 + Placebo	Cocrystal Pharma	Phase 1/2	29